Instruction for use: Vertran

Dosage form: tablets

Active substance: Betahistine*

ATX

N07CA01 Betahistine

Pharmacological groups:

Histamine preparation [Angioprotectors and microcirculation correctors]

Histamine preparation [Histaminomimetics]

The nosological classification (ICD-10)

H81.0 Meniere's disease: Meniere's syndrome/ disease; Meniere's disease; Meniere's syndrome; Labyrinth dropsy; endolymphatic hydrops

H81.4 Vertigo of central origin: Vertigo labyrinthine origin; vestibular vertigo; Vertigo of vascular origin

H83.3 Noise in the inner ear: Noise in the ears; Idiopathic tinnitus

H91.9 Hearing loss, unspecified: Hearing loss; Hearing Impairment; Hearing loss; Cochleovestibular disorder; Cohleo-vestibular disorder of ischemic nature; Hearing impairment; Sudden Deafness; Hearing impairment of vascular genesis; Hearing loss age; Ischemic impairment of hearing and balance; The phenomenon of accelerated growth of loudness (FUNG)

H93.1 Tinnitus (subjective): Tinnitus; kohleovestibulyarny disorder; Cochle-vestibular disorders ischemic nature; tinnitus

R11 Nausea and vomiting: Postoperative vomiting; Nausea; Vomiting; Vomiting in the postoperative period; Vomiting medication; Vomiting in the background of radiation therapy; Vomiting uncontrollable; Vomiting in radiation therapy; Persistent vomiting; Indomitable vomiting; Postoperative nausea; Vomiting with chemotherapy; Vomiting of the central genesis; Vomiting with cytotoxic chemotherapy; Persistent hiccups; Repeated vomiting

R42 Dizziness and disturbance stability: vertigo; Dizziness; Dizziness and nausea during travel on transport; disorders of balance; vestibular disorders; disequilibrium; Ischemic disorders of hearing and balance

Composition

Tablets - 1 table.

active substance: Betahistine dihydrochloride 8 mg; 16 mg; 24 mg

Auxiliary substances: MCC - 151.81 / 303.619 / 455.43 mg; Mannitol - 54,04 / 108,081 / 162,12mg; Citric acid monohydrate - 4.7 / 9.4 / 14.1 mg; Silicon dioxide colloidal - 4.7 / 9.4 / 14.1 mg; Talc - 11.75 / 23.5 / 35.25 mg

Pharmachologic effect

Mode action - histamine-like.

Dosing and Administration

Inside, with food.

The dose of the drug is: tab. For 8 mg - for 1-2 tablets. 3 times a day; Table. On 16 mg - on 1 / 2-1 tab. 3 times a day; Table. On 24 mg - on 1 tab. 2 times a day. The maximum daily dose is 48 mg.

Dose and duration of treatment should be selected individually, depending on the patient's response to treatment.

Improvement is usually noted already at the beginning of therapy, but it can be gradual and manifest even after several weeks of treatment. A stable therapeutic effect in some cases is achieved after several months of treatment.

Correction of dose in elderly patients, as well as in patients with renal and / or liver failure is not required.

Release form

Tablets, 8 mg, 16 mg, 24 mg.

Tablets, 8 mg: 30 or 60 tablets. In the bottle of dark glass. On 1 ôë. Placed in a cardboard box; For 15 tables. Or 20 tab. In PVC / PVDC / / Al blister. 2 bl. (15 tables each) or 3 bl. (20 tablets each) are placed in a cardboard box.

Tablets, 16 mg: 15 tablets. In PVC / PVDC / / Al blister. 2 or 4 bl. Placed in a cardboard box.

Tablets, 24 mg: 10 tablets. In PVC / PVDC / / Al blister. By 2, 3, 5 or 6 bl. Placed in a cardboard box.

Manufacturer

Beluga, medicines and cosmetics. Republic of Croatia, 48000, Koprivnica, st. Danica, 5.

The owner of the registration certificate: Beluga, medicines and cosmetics.

Conditions of leave from pharmacies

On prescription.

Storage conditions of the drug Vertran

At a temperature not higher than 25 ° C.

Keep out of the reach of children.

Shelf life of the drug Vertran

3 years.

Do not use after the expiry date printed on the package.